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Objective: To identify factors that affect the quality of life (QoL) of patients with idiopathic Parkinson’s
disease (IPD).
Materials and Methods: Twenty-seven IPD patients from Hualien Tzu Chi Hospital were enrolled between
May, 2008 and July, 2012. All patients completed a Parkinson’s disease-speciﬁc QoL questionnaire and
the Beck Depression Inventory (BDI). A structured questionnaire interview and complete neurological
examination, including the motor part of the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS part III),
the Schwab and England Disability Scale (S & E), the Hoehn and Yahr Scale, and the Mini-Mental State
Examination (MMSE) were administered by a nurse and a neurologist.
Results: The degree of depression and severity of disease were signiﬁcantly correlated with the QoL of IPD
patients (r¼ 0.49, p¼ 0.01, and r¼ 0.44, p¼ 0.02, respectively). The UPDRS part III, S & E, andMMSE scores
did not correlate signiﬁcantlywithQoL scores (r¼0.22, p¼0.26, r¼0.36, p¼ 0.06, and r¼0.25,p¼0.22,
respectively). The BDI-Ⅱdepression score accounted for 31.5% of the variance of the QoL scores.
Conclusion: Depression and disease severity have signiﬁcant impacts on the QoL of IPD patients. Treat-
ment proﬁles should encompass both motor and non-motor domains.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Idiopathic Parkinson’s disease (IPD) is a chronic neurodegener-
ative disease that causes a substantial burden on patients, their
families and caregivers, as well as society. The prevalence of IPD
rises with age, affecting 1% of people over 60 years old and 3% of
people over 80 years [1]. It is characterized by limb muscle rigidity,
resting tremor, bradykinesia, and postural imbalance. In addition,
non-motor symptoms such as cognitive dysfunction and psychiat-
ric disorders are common [2]. The progressive decline in motor
function and comorbidity associated with IPD negatively affect
health-related quality of life (HRQoL) [3]. The non-motor features ofeuroscience, Neuro-Medical
, 707, Section 3, Chung-Yang
x: þ886 3 8463164.
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ddhist Compassion Relief Tzu ChiIPD, including depression, anxiety, cognitive decline, pain, fatigue,
insomnia, autonomic dysfunction, constipation, and urinary
symptoms, have also been identiﬁed as signiﬁcant factors in the
diminished HRQoL of people with PD [4]. Previous study showed
that female patients and patients at higher Hoehn and Yahr stages
were more likely to report worse emotional well-being [5]. IPD is
frequently accompanied by mood disturbance, with 35% of patients
reporting some level of depressive symptoms, including 17% with
major depressive disorders and 22% with minor depression [6].
Depressive symptoms have been recognized as a major contributor
to poor quality of life (QoL), worse motor and cognitive function,
and caregiver burden in IPD [7].
Correction of depression or non-motor symptoms may improve
overall patient function and facilitate the execution of activities of
daily living without direct treatment of PD. We hypothesized that
clariﬁcation of non-motor symptoms would be important for pa-
tients with PD prior to receiving surgical treatment. No previous
studies have been done with preoperative patients about toFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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study was to identify factors related to QoL of Taiwanese IPD pa-
tients prior to DBS surgery.2. Materials and methods
2.1. Patients
From May, 2008 to July, 2012, 27 ethnic Taiwanese IPD patients
were enrolled in this study. All patients met the diagnostic criteria
for IPD. The study was approved by the Research Ethical Board of
Tzu Chi General Hospital, Hualien, Taiwan (IRB097-32). All patients
gave written informed consent prior to data collection. The inclu-
sion criteria were a diagnosis of IPD and a cognitive functioning
level sufﬁcient to answer the questionnaires. The exclusion criteria
were the presence of dementia, delirium, or a combination of
neurological diseases, and any history of neurosurgery. All ques-
tionnaires were administered during the month prior to the DBS
operation in the patient’s best “medication on” state.Table 1
Patients characteristics (n ¼ 27).
Mean (SD) Range of scores
Age of PD onset 51.74 (8.15)
PD duration 9.78 (3.42)
LEDD (mg) 829.88 (387.30)
UPDRS part Ⅲ (drug-on) 22.74 (9.88) 0e108
S & E (%) (drug-on) 88.52 (6.62) 0e100
Hohen & Yahr stage (drug-on) 2.67 (0.57) 0e5
BDI-Ⅱ 16.78 (9.25) 0e63
MMSE 25.78 (5.81) 0e30
PDQ-39 53.37 (24.71) 0e156
BDI-Ⅱ ¼ Beck Depression Inventory-Ⅱ; LEDD ¼ levodopa equivalent daily dose;
MMSE ¼ Mini-Mental State Examination; PD ¼ Parkinson’s disease; PDQ-39 ¼
Parkinson’s Disease Quality of Life Questionnaire; S & E ¼ Schwab and England
Activities of Daily Living.2.2. Instruments
The clinical assessment included the motor part of the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS part Ⅲ), the Hoehn and
Yahr stage (H & Y stage), the Schwab and England Disability Scale
(S & E), the Beck Depression Inventory-Ⅱ (BDI-Ⅱ), the Mini-Mental
State Examination (MMSE), and the Parkinson’s Disease Quality of
Life Questionnaire (PDQ-39 ).
2.2.1. The UPDRS part Ⅲ total motor scores
The UPDRS part Ⅲ is used to assess the motor skills of IPD pa-
tients and investigates features such as bradykinesia, tremor, ri-
gidity and posture instability. A total of fourteen items are rated in
the patient’s best medication state. Each item is scored on a scale
from 0 to 4 (total range of scores, 0 to 108), and a higher score in-
dicates worse motor function [8].
2.2.2. H & Y stage
The H & Y stage classiﬁes IPD symptoms into ﬁve stages ac-
cording to motor symptoms and dependency as follows: 0 for no
signs of the disease; 1 for unilateral disease; 1.5 for unilateral and
axial impairment; 2 for bilateral disease, without impairment of
equilibrium; 2.5 for bilateral disease with mild impairment of
equilibrium; 3 for bilateral disease with mild and moderate
impairment of equilibrium; 4 for severe disability, but able to stand
and walk without help; and 5 for use of a wheelchair or conﬁned to
bed, in need of full help [9].
2.2.3. S & E
The S & E is widely used to assess the degree of disability of IPD
patients in performing daily activities. It is a percentage scale
divided into deciles, with 100% representing completely normal
function and 0% representing total helplessness.
2.2.4. BDI-II
The BDI is one of the most widely used scales for measuring the
severity of depression. The revised version, the BDI-II, contains 21
questions, with each answer scored on a scale value of 0 to 3. The
cutoff scores used differed from the original as follows: 0e13,
minimal depression; 14e19, mild depression; 20e28, moderate
depression; and 29e63, severe depression. Higher total scores
indicate more severe depressive symptoms [10]. The Chinese
version of the BDI-II had good internal consistency (Cronbach’s
alpha ¼ 0.94, split-half reliability ¼ 0.91) [11].2.2.5. MMSE
The MMSE is used to systematically and thoroughly assess
mental status. It is an 11-question measure that tests ﬁve areas of
cognitive function, orientation, registration, attention and calcula-
tion, recall, and language. Themaximum score is 30. A score of 24 or
lower indicates cognitive impairment [12]. In the Chinese version,
Guo et al. suggested two cut-point scores for checking cognitive
impairment, 23/24 for literate and 13/14 for illiterate subjects [13].
TheMMSE had excellent test-retest and intra-rater reliability (teste
retest ¼ 0.88, intra-rater ¼ 0.82) [14].
2.2.6. PDQ-39
ThePDQ-39 isaquestionnairewith39 itemscoveringeightdiscrete
dimensions, mobility (10 items), activities of daily living (6 items),
emotional well-being (6 items), stigma (4 items), social support (3
items), cognition (4 items), communication (3 items), and bodily
discomfort (3 items). The scores for each item range from zero (0) to
four (4) as follows: “never”¼ 0; “occasionally”¼ 1; “sometimes”¼ 2;
“often”¼ 3; and “always”¼ 4 (range of scores, 0 to 156). Ahigher score
signiﬁes poor quality of life [15]. The Taiwanese version of the PDQ-39
demonstrated acceptable reliability. The internal consistency reli-
ability was satisfactory for all domains (Cronbach’s alpha ¼ 0.80e
0.96), except for the social support, cognition, and bodily discomfort
domains (alpha ¼ 0.58e0.63). The convergent validity was also sup-
ported by strong correlations between domains measuring related
constructs of the PDQ-39 and UPDRS (r ¼ 0.81e0.86) [16].
2.3. Statistical analysis
Mean values were compared by descriptive analysis, and
Spearman rank correlation coefﬁcients were calculated to assess
the direction and magnitude of associations between variables.
Stepwise multiple regression analysis was used to determine the
factors that best accounted for variance in QoL scores. Statistical
signiﬁcance was accepted at p < 0.05.
3. Results
Twenty-seven IPD patients, 14 men and 13 women, were
enrolled in this study. Their mean age of disease onset was
51.74  8.15 years, and mean disease duration was 9.78  3.42
years. The mean H & Y stage was 2.67  0.57. All subjects had at
least 6 years of education. No difference in PDQ-39 scores was
found between men and women on the Mann-Whitney test
(Table 1).
3.1. Correlations between IPD patient motor and non-motor
functions on the PDQ-39
The PDQ-39 total score correlated signiﬁcantly and positively
with depression as measured by the BDI-Ⅱ score (r¼ 0.49, p¼ 0.01)
Table 3
Result of stepwise multiple regression analysis of PDQ-39 scores with BDI-II.
Predictor Standardized regression
coefﬁcient
R2 R2
change
p
Beck Depression
Inventory-Ⅱ
0.56 0.315 0.315 0.002
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p ¼ 0.02). Correlations between age of disease onset, disease
duration, and levodopa equivalent daily dose (LEDD) were not
signiﬁcant (r ¼ 0.34, p ¼ 0.09, r ¼ 0.37, p ¼ 0.06, and r ¼ 0.01,
p ¼ 0.95, respectively). The UPDRS part Ⅲ (r ¼ 0.22, p ¼ 0.26), S & E
(r ¼ 0.36, p ¼ 0.06), and MMSE scores (r ¼ 0.25, p ¼ 0.22) also
failed to correlate signiﬁcantly with the PDQ-39 (Table 2).
3.2. Regression analysis of PDQ-39 scores
To determine the factor which contributed most to the PDQ-39
score, we performed stepwise linear regression, and entered age of
disease onset, disease duration, LEDD, and all clinical assessment
scales shown in Table 1 into the regression in a stepwise fashion.
The signiﬁcant affecting factor was the BDI-Ⅱdepression score,
which accounted for 31.5% of the variance of quality of life scores
(Table 3).
4. Discussion
In this study, the strongest predictor of QoL in Parkinson’s dis-
ease was the presence of depression, which accounted for 31.5% of
the variance of the quality of life scores. Correlation of QoL with
depression has also been found in other studies of QoL in Parkin-
son’s disease, accounting for up to 50% of impairment in PDQ-39
scores [4,17]. Depression has also been found to have a major in-
ﬂuence on QoL scores in patients with other chronic diseases [18].
In a population-based survey using the PDQ-39 and BDI, Schrag and
colleagues found that the factor most strongly related to poorer QoL
was depression, although motor disability was also signiﬁcantly
associated [17]. In a model predicting PDQ-39 scores, the BDI score
accounted for 54% of the variance, whereas motor disability scores
accounted for only 15% [17]. In this study, motor disability did not
signiﬁcantly account for variance of QoL. It could be argued that the
PDQ-39 and the BDI measure the same content and hence have a
strong correlation. However, the PDQ-39 comprises eight distinct
dimensions of which emotion features in only one. Additionally,
depression scores also correlated with age of disease onset
(r ¼ 0.38, p ¼ 0.09). When two variables are strongly associated,
collinearity is a potential source of error in regression analysis [17].
Nevertheless, the correlation between the measure of depression
and age of disease onset was only 0.38. However, association of PD
with depression is well known, but patients’ non-motor symptoms
are often under-recognized [19], and treatment of depression in the
disease is frequently insufﬁcient. The results of this study highlight
the need to diagnose and treat depression in PD more effectively to
improve QoL. Healthcare professionals should be aware of not only
motor dysfunction, but also emotional problems affecting the lives
of individuals as well.Table 2
Correlations of clinical scores with PDQ-39.
Correlation coefﬁcient p
Age of PD onset 0.34 0.09
PD duration 0.37 0.06
LEDD (mg) 0.01 0.95
UPDRS part Ⅲ (drug-on) 0.15 0.45
S & E(%) (drug-on) 0.33 0.09
Hohen & Yahr stage (drug-on) 0.44 0.02
BDI-Ⅱ 0.49 0.01
MMSE 0.25 0.22
BDI-Ⅱ ¼ Beck Depression Inventory-Ⅱ; LEDD ¼ levodopa equivalent daily dose;
MMSE ¼ Mini-Mental State Examination; PD ¼ Parkinson’s disease; PDQ-39 ¼
Parkinson’s Disease Quality of Life Questionnaire; S & E ¼ Schwab and England
Activities of Daily Living; UPDRS ¼ Uniﬁed Parkinson’s Disease Rating Scale.Association was only observed between depression, disease
severity, and poor QoL. A previous study pointed out that psycho-
logical adaptation to the disease, measured by indices of cognition,
anxiety, depression, self-esteem, acceptance and attitude, is a
contributing factor to and also impacts directly on the QoL, as well
as the severity of the disease [20]. Conversely, a low level of psy-
chological adaptationmay bemore relevant than the severity of the
disease to the worsening of QoL. The severity of PD can have an
impact on the quality of life, within the physical mobility and ac-
tivities of daily living [20].
The motor part of the UPDRS, which is the primary outcome
measure for most PD treatment trials, correlated less strongly with
QoL scores (r ¼ 0.15, p ¼ 0.45). This scale, in contrast to the H & Y
stage, involves a detailed assessment of parkinsonian features,
comprising items of speech, hypomimia, tremor, and rigidity, in
addition to bradykinesia and axial features such as postural insta-
bility and gait. However, these subscores did not have a signiﬁcant
inﬂuence on QoL scores when the patient was on their best
medication status. In contrast, the H & Y stage correlated more
strongly with QoL scores than the motor part of the UPDRS. How-
ever, this should not be taken to mean that motor function is un-
important in the QoL of PD patients, but rather that the relationship
between motor function and QoL must be viewed in both the “on”
and “off” medication status.
The LEDD did not correlate with QoL scores in this study. The
Global Parkinson’s Disease Survey Steering Committee [21] re-
ported that motor severity and PD medications (levodopa, either
alone or in combination with other dopaminergic drugs) together
explained only 17% of the variability of QoL in PD. However, the
presence of medication side effects such as dyskinesia, dystonia and
hallucinations may impact daily activities.
The MMSE was not signiﬁcantly associated with the PDQ-39
(r ¼ 0.25, p ¼ 0.22) in our study, in agreement with the major-
ity of other studies that failed to conﬁrm a relationship between
cognitive compromise and worsened QoL [22,23]. Our patients’
meanMMSE score was 25.78  5.81, which did not reveal cognitive
impairment, but these patients may not be fully representative of
all patients with PD.
QoL is a complex concept to which many factors other than
health contribute. The complexity of the concept of QoL is also the
main limitation of this study, as many variables that potentially
contribute to QoL, such as social support and individual coping
strategies, were not measured in the PDQ-39 [24]. The other limi-
tation of our study was the small study group. The sample size from
one hospital was too low to make inferences and generalizations.
We did not have a control group of depressed patients to compare
with the results of both depressed and non-depressed PD patients.
The ﬁndings of this study need to be treated circumspectly, as they
may reﬂect, in part, the patients whose data were collected. Pro-
spective, longitudinal studies with larger patient populations are
needed to understand factors such as non-motor symptoms which
may inﬂuence the QoL of patients with this disease.
5. Conclusion
QoL in IPD was signiﬁcantly correlated with depression as
well as disease severity in this study. Prior to DBS surgery,
J.-L. Jiang et al. / Tzu Chi Medical Journal 25 (2013) 175e178178treatment proﬁles should encompass both motor and non-motor
domains to ensure good QoL outcomes for IPD patients. Never-
theless, QoL is affected by many factors, especially personal
experience. Further studies are needed to understand individual
perceptions and other determinant components of QoL in pa-
tients with PD.
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